VectorY Therapeutics, VTx-002, PIONEER-ALS, ALS, Amyotrophic Lateral Sclerosis, TDP-43, Vectorized Antibody, Neurodegenerative Disease, Gene Therapy

AMSTERDAM, Netherlands and BOSTON, Mass. — September 29, 2026 VectorY Therapeutics announced the expansion of its global Phase 1/2...